港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

483.155

-13.603-2.74%

漲家數：7

跌家數：23

平家數：3

市盈率：- -

高：496.758

開：496.758

低：480.328

收：496.758

成交量：1.15億

成交額：26.12億

市值：3,069.30億

流通市值：2,732.98億

資料載入中...

微創心通-B(02160)：延遲刊發2026年中期業績

微創心通-B(02160)9月1日起停牌

迪哲醫藥(688192.SH)：與阿斯利康就舒沃哲®授權許可協議生效

白宮再與9家藥企達成降價協議

2026版國家基藥目錄今起施行：4款國產創新藥納入

亞洲藥企股價方面或將作出反應特朗普將九家製藥企業納入醫療補助計劃

环球市场播报

恒瑞醫藥ADC創新藥一項Ⅲ期臨床研究達到主要終點；力諾藥包籌劃赴港上市丨醫藥早參

每日经济新闻

億騰嘉和(06998.HK)8月31日斥資61.99萬港元回購39.75萬股

億騰嘉和(06998)8月31日斥資61.99萬港元回購39.75萬股

新股消息 | 普萊醫藥二次遞表港交所

特朗普稱九家新製藥企業承諾降價

上海市衞生和健康發展研究中心主任金春林接受本報記者專訪詳解2026版國家基藥目錄調整邏輯

再鼎醫藥（ZLAB）盤中震盪走軟跌4.43% 中期歸屬於上市公司股東淨虧損按年擴大14%

億騰嘉和(06998)董事會主席倪昕計劃斥資最高100萬美元增持公司股份

A股醫藥中報收官，創新藥企批量扭虧

中國抗體-B(03681.HK)上半年研發成本持續加碼產品管線收穫多項里程碑

啓明醫療-B(02500.HK)發布中期業績，歸母虧損1.91億元按年增加41.9%

騰盛博藥-B(02137.HK)8月31日斥資1.82萬港元回購2萬股

歌禮制藥-B(01672)發布中期業績股東應占虧損3.2億元按年增加263.5%

歌禮制藥-B：董事會建議不派發中期股息

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/BK1574/news?page=16"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":483.15506,"timestamp":1789114133774,"preClose":496.75812,"halted":0,"volume":115323363,"delay":0,"changeRate":-0.027384,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未開盤","change":-13.603058,"latestTime":"09-11 16:00:00","open":496.75812,"high":496.75812,"low":480.32812,"amount":2611810568,"amplitude":0.033074,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"pbRate":3.606253,"peRate":160.422718,"turnoverRate":0.004215,"increases":6,"decrements":25,"flats":1,"marketCap":306930068880,"floatMarketCap":273297591592},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":496.75812,"amplitude":0.033074,"preClose":496.75812,"low":480.32812,"pbRate":"3.606253","latestPrice":483.15506,"volume":115323363,"delay":0,"open":496.75812,"prevYearClose":556.26263,"prevWeekClose":483.155,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":532.025,"twentyDayClose":518.327,"sixtyDayClose":434.471,"secType":"PLATE","market":"HK","turnoverRate":0.004215,"peRate":160.422718,"marketCap":306930068880,"floatMarketCap":273297591592,"timestamp":1789114133774,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":7,"down":23,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:16,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664881038","title":"微創心通-B(02160)：延遲刊發2026年中期業績","url":"https://stock-news.laohu8.com/highlight/detail?id=2664881038","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664881038?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 09:02","pubTimestamp":1788224544,"startTime":"0","endTime":"0","summary":"智通财经APP讯，微创心通-B(02160)发布公告，预计2026年中期业绩和2026年中期报告的发布将推迟，因为董事会认为公司需要额外的时间来：(i)确定业主及其联系人的背景及其与公司的关系;(ii)评估租赁条款的商业合理性，包括但不限于租金和保证金;及(iii)评估与租赁有关的额外装修费用的合理性和适当的会计处理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490111.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","02918","BK1239","02160","BK1583","BK1225","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664881470","title":"微創心通-B(02160)9月1日起停牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2664881470","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664881470?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 08:55","pubTimestamp":1788224120,"startTime":"0","endTime":"0","summary":"智通财经APP讯，微创心通-B(02160)发布公告，该公司股份将于今天(1/9/2026)上午九时正起暂停买卖。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490103.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02918","BK1100","BK1239","02160","BK1583","BK1574","BK1225"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664881161","title":"迪哲醫藥(688192.SH)：與阿斯利康就舒沃哲®授權許可協議生效","url":"https://stock-news.laohu8.com/highlight/detail?id=2664881161","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664881161?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 08:44","pubTimestamp":1788223497,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药(688192.SH)发布公告，公司于2026年7月14日与AstraZeneca UK Limited(以下简称“阿斯利康”)签署《许可协议》，授予阿斯利康在全球范围内独家开发、商业化舒沃哲®的权利。协议约定的协议生效条件已全部满足，协议于2026年8月31日正式生效。阿斯利康将于今年第四季度在美国实现舒沃哲®商业化。公司将获得阿斯利康支付的一次性、不可返还的首付款6亿美元，最高达4 亿美元的临床开发里程碑款项以及最高达5亿美元的销售里程碑款项，此外公司将获得按舒沃哲®全球销售额最高到低双位数的阶梯式比例的特许权使用费。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490099.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","159938","BK1574","BK1161","BK1515","688192","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664861881","title":"白宮再與9家藥企達成降價協議","url":"https://stock-news.laohu8.com/highlight/detail?id=2664861881","media":"格隆汇","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664861881?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 08:32","pubTimestamp":1788222773,"startTime":"0","endTime":"0","summary":"九家药企承诺近期共向美国本土制造业投资至少196亿美元","market":"fut","thumbnail":"https://img3.gelonghui.com/7fb49-d06c3ddc-ca0b-4a59-8f2e-8b249cbca8db.jpg?guru_height=2304&guru_width=3456&guru_size=1041191","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/7fb49-d06c3ddc-ca0b-4a59-8f2e-8b249cbca8db.jpg?guru_height=2304&guru_width=3456&guru_size=1041191"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/6435688","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["01477","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664864788","title":"2026版國家基藥目錄今起施行：4款國產創新藥納入","url":"https://stock-news.laohu8.com/highlight/detail?id=2664864788","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664864788?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 07:29","pubTimestamp":1788218967,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["06978","159992","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664861408","title":"亞洲藥企股價方面或將作出反應 特朗普將九家製藥企業納入醫療補助計劃","url":"https://stock-news.laohu8.com/highlight/detail?id=2664861408","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664861408?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 07:16","pubTimestamp":1788218160,"startTime":"0","endTime":"0","summary":"特朗普政府宣布已与九家生物技术及制药企业达成全新药品定价协议，亚洲制药企业股价方面或做出反应。作为该协议的一部分，上述企业将为各州医疗补助计划的门诊药物提供折扣。各州的采购定价将对标这些企业在海外市场的售价。 澳大利亚生物制药巨头 CSL 在书面声明中表示，预计 2027 财年不会出现重大实质性影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-09-01/doc-iniqhmwh1505536.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","01477","XHS","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664886163","title":"恒瑞醫藥ADC創新藥一項Ⅲ期臨床研究達到主要終點；力諾藥包籌劃赴港上市丨醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2664886163","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664886163?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 07:02","pubTimestamp":1788217348,"startTime":"0","endTime":"0","summary":"恒瑞医药ADC创新药一项Ⅲ期临床研究达到主要终点；力诺药包筹划赴港上市丨医药早参","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609013860561844.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609013860561844.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09939","IBBQ","150130","MEDX","06978","159938","BK0235","301188","BK1161","BK1515","BK1574","LNGR","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664855886","title":"億騰嘉和(06998.HK)8月31日斥資61.99萬港元回購39.75萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664855886","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664855886?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 06:36","pubTimestamp":1788215812,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","06998","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664688685","title":"億騰嘉和(06998)8月31日斥資61.99萬港元回購39.75萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664688685","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664688685?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 06:36","pubTimestamp":1788215812,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亿腾嘉和(06998)发布公告，于2026年8月31日，该公司斥资61.99万港元回购39.75万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490047.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06998","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664886895","title":"新股消息 | 普萊醫藥二次遞表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2664886895","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664886895?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 06:34","pubTimestamp":1788215697,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","09939","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664888816","title":"特朗普稱九家新製藥企業承諾降價","url":"https://stock-news.laohu8.com/highlight/detail?id=2664888816","media":"第一财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664888816?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 03:38","pubTimestamp":1788205099,"startTime":"0","endTime":"0","summary":"美国总统特朗普在白宫活动上表示，爱尔康（Alcon）、安斯泰来制药（AstellasPharma）、BeOneMedicines、BridgeBio、杰特贝林（CSLBehring）、协和麒麟（KyowaKirin）、太阳制药（SunPharma）、梯瓦制药（TevaPharmaceuticals）以及优时比（UCB），将根据与特朗普政府达成的新协议下调药品价格。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609013860536286.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609013860536286.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","01477","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664610007","title":"上海市衞生和健康發展研究中心主任金春林接受本報記者專訪 詳解2026版國家基藥目錄調整邏輯","url":"https://stock-news.laohu8.com/highlight/detail?id=2664610007","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664610007?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 01:08","pubTimestamp":1788196080,"startTime":"0","endTime":"0","summary":"    9月1日，时隔八年全新修订的《国家基本药物目录(2026版)》正式落地实施，目录共收录药品794种，针对性补齐创新药、中药创新品种、儿童用药三大临床短板。 &en ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260901/c679463104.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260901/c679463104.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["LNGR","BK1574","BK1161","06978","IBBQ","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663049960","title":"再鼎醫藥（ZLAB）盤中震盪走軟跌4.43% 中期歸屬於上市公司股東淨虧損按年擴大14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663049960","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663049960?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 23:02","pubTimestamp":1788188527,"startTime":"0","endTime":"0","summary":"金吾财讯 | 再鼎医药（ZLAB）盘中震荡走软，截至发稿，最新报24.93美元，下跌4.43%，成交额621.24万美元。消息面上，再鼎医药新近披露2026年中期财报，年初至报告期末实现营业收入2.06亿美元，同比下降5%；归属于上市公司股东的净亏损为1.02亿美元，同比扩大14%。截至2026年6月30日，公司资产合计10.75亿美元，负债合计4.68亿美元，基本及摊薄每股亏损为0.09美元。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/N2NlYWIzMDQ5MjY5YzU0NWM0NDMwZTE4ZDQ3MjY3ODIxNTA5MDg=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/N2NlYWIzMDQ5MjY5YzU0NWM0NDMwZTE4ZDQ3MjY3ODIxNTA5MDg=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305520","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","09688","LU2488822045.USD","BK4526","BK1588","BK4585","BK4548","BK4588","ZLAB","BK4139","BK4531","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663010530","title":"億騰嘉和(06998)董事會主席倪昕計劃斥資最高100萬美元增持公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2663010530","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663010530?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 22:55","pubTimestamp":1788188100,"startTime":"0","endTime":"0","summary":"股份购买将自2026年8月31日起进行，预计总金额最高为100万美元。根据本公司所得资料及董事所知所信，倘若增持股份计划得以实施，本公司将继续维持已发行股份的足够公众持股量。董事会认为，建议股份购回符合本公司及其股东整体最佳利益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489981.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"亿腾嘉和(06998)董事会主席倪昕计划斥资最高100万美元增持公司股份","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","BK1583","06998"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663048920","title":"A股醫藥中報收官，創新藥企批量扭虧","url":"https://stock-news.laohu8.com/highlight/detail?id=2663048920","media":"全球财说","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663048920?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 22:47","pubTimestamp":1788187620,"startTime":"0","endTime":"0","summary":"01中报收官，业绩分化创新药是本轮中报业绩变化最明显的方向之一。石药创新同样依靠BD兑现实现业绩反转。一条兑现路径是海外BD授权。大额BD的价值不只是改善当期利润表，即首付款可迅速补充现金储备，海外大型药企愿意支付较高金额本身也是对国产创新药研发能力的市场化验证。BD相关收入的持续兑现能力，仍是当前观察创新药企基本面的核心落脚点。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-08-31/doc-iniqfqsp8765429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["KURE","06978","LNGR","159992","MEDX","IBBQ","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663012650","title":"中國抗體-B(03681.HK)上半年研發成本持續加碼 產品管線收穫多項里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=2663012650","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663012650?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 22:35","pubTimestamp":1788186935,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","03681","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663006123","title":"啓明醫療-B(02500.HK)發布中期業績，歸母虧損1.91億元 按年增加41.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663006123","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663006123?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 21:37","pubTimestamp":1788183457,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1100","02500","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663061720","title":"騰盛博藥-B(02137.HK)8月31日斥資1.82萬港元回購2萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2663061720","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663061720?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 21:33","pubTimestamp":1788183206,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1587","BK1574","BK1161","02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663006583","title":"歌禮制藥-B(01672)發布中期業績 股東應占虧損3.2億元 按年增加263.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663006583","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663006583?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 21:24","pubTimestamp":1788182651,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布截至2026年6月30日止六个月业绩，该集团取得收入总额人民币5297.9万元，同比减少48.9%;研发成本3.42亿元，同比增加132.7%;公司权益股东应占亏损3.2亿元，同比增加263.5%;每股亏损30.74分。人体数据表明，ASC50有望成为同类首创及同类最佳口服小分子IL-17A抑制剂。ASC51为一款强效、选择性及每日一次口服STAT6降解剂并已具备向FDA 提交IND申请条件的候选药物。ASC52有望成为同类最佳IL-17AA、AF及FF口服环肽拮抗剂，预计将于2026年第四季度向FDA递交IND。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489861.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","01672","01477","BK1161","BK1515","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162031632","title":"歌禮制藥-B：董事會建議不派發中期股息","url":"https://stock-news.laohu8.com/highlight/detail?id=1162031632","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162031632?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 21:18","pubTimestamp":1788182334,"startTime":"0","endTime":"0","summary":"歌礼制药-B（01672.HK）宣布，其董事会已决定不建议就中期业绩派发任何股息。这一决定反映出公司在当前阶段的财务策略与资本配置考量。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","01672","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":18,"pageCount":16,"totalSize":342,"code":"91000000","status":"200"}]}}